GlassScriptPhysician profile
Kara Danielle Davis
NPI 1760140107
$1,268.31
in general payments reported to CMS, 2019-2025
24 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $52.00 · 2023: $178 · 2024: $576 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172.37 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $155.90 | 2024-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $118.24 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $108.68 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $101.18 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.33 | 2024 | Farxiga |
| Pfizer INC. | $76.92 | 2023-2025 | |
| Abbvie INC. | $60.95 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $59.77 | 2024-2025 | Capvaxive, Gardasil 9, Dificid |
| Phathom Pharmaceuticals, INC. | $39.94 | 2025 | Voquezna |
| Medtronic, INC. | $33.83 | 2025 | Synchromedii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.86 | 2024 | Jardiance |
| Urovant Sciences INC | $31.26 | 2022 | |
| Glaukos Corporation | $22.20 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Vanda Pharmaceuticals INC. | $21.90 | 2025 | Hetlioz, Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $20.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.25 | 2024 | |
| Abbott Laboratories | $17.68 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2025 | Rexulti |
| Astellas Pharma US INC | $16.83 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.75 | 2024 | Caplyta |
| Exact Sciences Corporation | $15.46 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
| Insulet Corporation | $14.79 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.